T. Rowe Price Investment Management Inc. Sells 469,498 Shares of Enovis Co. (NYSE:ENOV)

T. Rowe Price Investment Management Inc. lowered its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 7.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163,136 shares of the company's stock after selling 469,498 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 10.84% of Enovis worth $270,439,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in ENOV. Vanguard Group Inc. lifted its holdings in shares of Enovis by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after purchasing an additional 75,348 shares during the period. DAVENPORT & Co LLC increased its position in shares of Enovis by 6.0% during the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock valued at $121,181,000 after acquiring an additional 157,216 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Enovis by 2.8% in the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after purchasing an additional 66,891 shares during the period. River Road Asset Management LLC lifted its stake in Enovis by 3.8% in the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock worth $54,339,000 after acquiring an additional 45,762 shares during the last quarter. Finally, Boston Partners lifted its position in shares of Enovis by 27.1% during the 4th quarter. Boston Partners now owns 1,048,532 shares of the company's stock worth $46,034,000 after buying an additional 223,816 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of Enovis in a report on Wednesday, April 9th.

Enovis Stock Performance

Enovis stock traded up $0.52 during mid-day trading on Tuesday, hitting $35.18. 88,627 shares of the company's stock traded hands, compared to its average volume of 750,720. The firm has a 50 day moving average price of $36.51 and a 200 day moving average price of $42.00. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a market cap of $2.01 billion, a PE ratio of -16.04 and a beta of 1.86. Enovis Co. has a one year low of $29.32 and a one year high of $56.43.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. On average, equities analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.